Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
8
×
life sciences
national
8
×
national blog main
national top stories
new york top stories
san francisco top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
alzheimer's disease
biotech
clinical trials
medicare
bristol-myers squibb
cancer immunotherapy
deals
drug prices
eli lilly
gene therapy
novartis
pfizer
roche
What
drug
8
×
bio
roundup
alzheimer’s
price
biogen’s
companies
nash
new
news
patients
prices
thanks
week
acquisitions
administration
aducanumab
advanced
albert
amyloid
angry
angst
annual
anti
approval
approved
arrival
assessed
atrophy
attention
award
bagged
benefited
biggest
billions
biogen
biopharmaceutical
biotech
bourla
brammer
Language
unset
unknown
Current search:
biogen
×
national
×
drug
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More